|
Presented by the Johns Hopkins University School of Medicine:
Supported by an educational grant from Merck & Co.
System Requirements
The following are required to view these programs:
Windows
- Windows 2000, ME, XP,
or Vista
- IE5 or later/NetScape 7/Mozilla 1.5/Opera 7/Firefox
Macintosh
- OS X or later
- Safari/Mozilla 1.5
All
- Flash Player 9
- Broadband (Cable/DSL or higher)
|
To View Newsletter, Please Read
the Following Information and Scroll Down
to the bottom of the Page
About the Program
Newsletter Overview
The newsletter will analyze and summarize and provide commentary regarding the clinical relevancy of the key studies on ARV therapies and therapeutic strategies presented at the 16th Conference on Retroviruses and Opportunistic Infections.
This program is sponsored for CME credit for US physicians by The Johns Hopkins University School of Medicine. The information in this educational activity was planned and produced in accordance with ACCME Essentials. All content was prepared by a distinguished faculty. This program is for health care providers who treat HIV-positive patients, there are no prerequisites.
Presented By:
Back to Top
Learning Objectives
At the conclusion of this activity, the participant should be able to:
-
Describe and explain the key new studies on ARV therapy presented at the 16th CROI.
-
Use the advances in clinical management of HIV-positive patients presented and discussed at the 16th CROI to improve patient care.
-
Analyze and apply data presented and discussed at the 16th CROI regarding the treatment of ARV-naive and experienced patients to analyze treatment options and construct appropriate ARV regimens.
Back to Top
Intended Audience
This activity is intended for physicians, physicians' assistants, and advanced practice nurses and other healthcare professionals involved in the treatment and management of patients with HIV infection. There are no prerequisites.
Back to Top
Accreditation Statement
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
The John Hopkins University School of Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Release Date: February 12, 2009
Expiration Date: February 12, 2010
The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of the CME activity.
Course Director
John Bartlett, MD
Professor, Johns Hopkins School of Medicine
Baltimore, Maryland
Faculty
Rafael E. Campo, MD
Professor of Clinical Medicine
Division of Infectious Diseases
University of Miami School of Medicine
Jackson Memorial Hospital
Miami, Florida
Calvin J. Cohen, MD, MS
Research Director, CRI New England,
Clinical Instructor, Harvard Medical School
Boston, Massachusetts
Edwin DeJesus, MD
Medical Director,
Orlando Immunology Center
Orlando, Florida
Richard A. Elion, MD
Associate Professor of Clinical Medicine,
George Washington University Medical Center
Washington, DC
Ian Frank, MD
Associate Professor of Medicine,
Director, Antiretroviral Clinical Research
University of Pennsylvania
Philadelphia, Pennsylvania
Graeme J. Moyle, MD, MB, BS
Associate Director of HIV Research,
Chelsea & Westminster Hospital
London, England
Paul Sax, MD
Clinical Director,
Brigham and Women’s Division of Infectious Diseases and HIV Program
Associate Professor of Medicine,
Harvard Medical School
Boston, Massachusetts
Instructions for Obtaining Continuing Medical Education Credit
In order to receive credit, participants must view the entire activity and complete a post test and activity evaluation online. Upon a successful score of 70% on the post test and completion of the evaluation, participants may print out their certificate. CME credit is available to US physicians only. Participants may access the post test by clicking on the link belwo and using the code retro1.
CME Test and Evaluation
Back to Top
Faculty Disclosure
As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The presenting faculty reported the following disclosure information:
Dr. John Bartlett:
- Sources of Funding for Research: Gilead.
- Consulting Agreements: Bristol-Myers Squibb; Tibotec; Abbott; GlaxoSmithKline.
- Speakers' Bureau/Honorarium Agreements: None.
- Financial Interests/Stock Ownership: None.
- Other: None.
Dr. Calvin Cohen:
- Sources of Funding for Research: Abbott; Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Roche; Pfizer; Tibotec.
- Consulting Agreements: Abbott; Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck; Roche; Pfizer; Tibotec.
- Speakers' Bureau/Honorarium Agreements: Abbott; Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck; Roche; Pfizer; Tibotec; Virco.
- Financial Interests/Stock Ownership: None.
- Other: ViralEd, LLC
Dr. Rafael Campo:
- Sources of Funding for Research: Abbott; Bristol-Myers Squibb; Gilead;
GlaxoSmithKline; Merck; Pfizer
- Consulting Agreements: Abbott; Merck; Tibotec; Vicro
- Speakers' Bureau/Honorarium Agreements: Abbott; Gilead; Merck; Pfizer;
Tibotec; Virco
- Financial Interests/Stock Ownership: Wife is an employee of Merck
- Other: Dr. Campo's wife is a Manager with Merck's Health Management
Services group for Tennessee, Louisiana, Florida, and Puerto Rico. She is
responsible for the asthma and diabetes disease areas; however, she does not
have responsibility for any of Merck's anit-infective, antiviral, or vaccine
products
Dr. Edwin DeJesus:
- Sources of Funding for Research: Boehringer Ingelheim; Abbott; Bristol-Myers
Squibb; Gilead; GlaxoSmithKline; Roche; Pfizer; Tibotec; Merck; Schering
Plough
- Consulting Agreements: Bristol-Myers Squibb; Gilead; GlaxoSmithKline;
Merck; Roche; Vertex
- Speakers' Bureau/Honorarium Agreements: Boehringer Ingelheim; Abbott;
Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck; Roche; Pfizer;
Tibotec; Schering Plough
- Financial Interests/Stock Ownership: None
- Other: None
Dr. Richard A. Elion:
- Sources of Funding for Research: Bristol-Myers Squibb; Gilead;
GlaxoSmithKline; Incyte; Tibotec.
- Consulting Agreements: Bristol-Myers Squibb Company; Gilead Sciences, Inc.;
GlaxoSmithKline; Incyte; Panacos.
- Speakers' Bureau/Honorarium Agreements: None.
- Financial Interests/Stock Ownership: None.
- Other: ViralEd, LLC.
Dr. Ian Frank:
- Sources of Funding for Research: Bavarian Nordic; Merck; Tibotec.
- Consulting Agreements: Abbott; Bristol-Myers Squibb; Gilead;
GlaxoSmithKline; Merck; Pfizer; Tibotec.
- Speakers' Bureau/Honorarium Agreements: Abott; Bristol-Myers Squibb;
Gilead; GlaxoSmithKline; Merck; Tibotec.
- Financial Interests/Stock Ownership: None.
- Other: None.
Dr. Graeme Moyle:
- Sources of Funding for Research: Abbott; Arnomed; Ardea; Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck; Pfizer; Tibotec.
- Consulting Agreements: Bristol-Myers Squibb; Gilead; GlaxoSmithKline;
Merck; Pfizer; Panacos; Tobira; Tibotec.
- Speakers' Bureau/Honorarium Agreements: Bristol-Myers Squibb; Boehringer-
Ingelheim; Gilead; GlaxoSmithKline; Merck; Pfizer; Tibotec.
- Financial Interests/Stock Ownership: None.
- Other: ViralEd, LLC.
Dr. Paul Sax:
- Sources of Funding for Research: Bristol-Myers Squibb; Merck; Pfizer.
- Consulting Agreements: Abbott; Bristol-Myers Squibb; Gilead;
GlaxoSmithKline.
- Speakers' Bureau/Honorarium Agreements: Abbott; Bristol-Myers Squibb;
Gilead; GlaxoSmithKline; Merck; Tibotec; Virco.
- Financial Interests/Stock Ownership: None.
- Other: None.
No speaker has indicated that their presentation will include information on off-label products.
Back to Top
The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
The Office of Continuing Medical Education (CME) at the Johns Hopkins University School of Medicine is committed to protect the privacy of its members and customers. Johns Hopkins University SOM CME maintains its Internet site as an information resource and service for physicians, other health professionals and the public. Continuing Medical Education at the Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in a CME Internet based program. Your information will never be given to anyone outside of the Johns Hopkins University School of Medicine’s CME program. CME collects only the information necessary to provide you with the services that you request.
Back to Top
Copyright © 2008 The Johns Hopkins University School of Medicine. All rights reserved.
|
